BioCryst Pharmaceuticals (NASDAQ:BCRX) & Ascletis Pharma (OTCMKTS:ASCLF) Head to Head Review

BioCryst Pharmaceuticals (NASDAQ:BCRX) and Ascletis Pharma (OTCMKTS:ASCLF) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Profitability

This table compares BioCryst Pharmaceuticals and Ascletis Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioCryst Pharmaceuticals	-51.71%	-76.36%	60.12%
Ascletis Pharma	N/A	N/A	N/A

Valuation & Earnings

This table compares BioCryst Pharmaceuticals and Ascletis Pharma”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCryst Pharmaceuticals	$874.84 million	2.70	$263.86 million	($1.78)	-5.23
Ascletis Pharma	N/A	N/A	N/A	N/A	N/A

BioCryst Pharmaceuticals has higher revenue and earnings than Ascletis Pharma.

Institutional and Insider Ownership

85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. 3.8% of BioCryst Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations for BioCryst Pharmaceuticals and Ascletis Pharma, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCryst Pharmaceuticals	0	4	8	0	2.67
Ascletis Pharma	0	0	0	0	0.00

BioCryst Pharmaceuticals presently has a consensus target price of $20.60, suggesting a potential upside of 121.36%. Given BioCryst Pharmaceuticals’ stronger consensus rating and higher probable upside, equities research analysts clearly believe BioCryst Pharmaceuticals is more favorable than Ascletis Pharma.

Summary

BioCryst Pharmaceuticals beats Ascletis Pharma on 7 of the 9 factors compared between the two stocks.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

About Ascletis Pharma

Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company offers Ritonavir tablet; and ASCLEVIR and GANOVO for the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, ASC42, ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is headquartered in Hangzhou, the People’s Republic of China.